Information Provided By: 
Fly News Breaks for May 26, 2016
FLXN
May 26, 2016 | 10:24 EDT
Wells Fargo analyst David Maris believes today's news from Flexion Therapeutics, that the company can proceed with its new drug application filing in Q4 for Zilretta, removes a major risk from the shares since the FDA did not ask for more data to be generated. Maris raised his price target range for Flexion shares to $29-$31 from $19-$21 and keeps an Outperform rating on the name. Maris expects Zilretta will be approved given its "pristine safety record and compelling clinical data."
News For FLXN From the Last 2 Days
There are no results for your query FLXN
